Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer

Journal of the National Cancer Institute

Volumn 106, Issue 2, 2014, Pages

  Liu, Ning Qing ^a,b,h   Stingl, Christoph ^b   Look, Maxime P ^a   Smid, Marcel ⁱ   Braakman, René B H ^a,b,j   De Marchi, Tommaso ^a,b   Sieuwerts, Anieta M ^a,b,i   Span, Paul N ^c   Sweep, Fred C G J ^c   Linderholm, Barbro K ^d,e   Mangia, Anita ^f   Paradiso, Angelo ^f   Dirix, Luc Y ^g   Van Laere, Steven J ^g   Luider, Theo M ^b   Martens, John W M ^a,b,i   Foekens, John A ^a,b,i,j   Umar, Arzu ^a,b,h,i,j  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^g Oncology Centre of Antwerp   (Belgium)

^h NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

ⁱ Cancer Genomics Centre   (Netherlands)

^j High Tech Campus 84   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; DISTANT METASTASIS; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER;

EID: 84893821461     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt376     Document Type: Article

References (34)

1. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.
2. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-4434.
3. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol. 2012;9(1):58-64.
4. Cheang M C U, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368-1376.
5. Rody A, Karn T, Liedtke C, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011;13(5):R97.
6. Hallett RM, Dvorkin-Gheva A, Bane A, Hassell JA. A gene signature for predicting outcome in patients with basal-like breast cancer. Sci Rep. 2012;2:227.
7. Kuo W-H, Chang Y-Y, Lai L-C, et al. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PloS One. 2012;7(9):e45831.
8. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 2010;12(5):R85.
9. Nagaraj N, Wisniewski JR, Geiger T, et al. Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol. 2011;7:548.
10. Geiger T, Madden SF, Gallagher WM, Cox J, Mann M. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res. 2012;72(9):2428-2439.
11. Umar A, Kang H, Timmermans AM, et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics. 2009;8(6):1278-1294.
12. Sieuwerts AM, Usher PA, Meijer-Van Gelder ME, et al. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem. 2007;53(7):1280-1288.
13. Van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol. 2009;27(4):542-549.
14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180-1184.
15. Liu NQ, Braakman R B H, Stingl C, et al. Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue. J Mammary Gland Biol Neoplasia. 2012;17(2):155-164.
16. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p. p. b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367-1372.
17. Mossman D, Somoza E. ROC curves, test accuracy, and the description of diagnostic tests. J Neuropsychiatry Clin Neurosci. 1991;3(3):330-333.
18. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
19. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H-J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21(17):3357-3365.
20. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001;93(13):979-989.
21. Rakha EA, El-Sayed ME, Green AR, Lee A H S, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25-32.
22. Liu NQ, Dekker L J M, Stingl C, et al. Quantitative proteomic analysis of microdissected breast cancer tissues: comparison of label-free and SILAC based quantification with shotgun, directed and targeted MS approaches [published online ahead of print August 20, 2013]. J Proteome Res. 2013;12(10):4627-4641.
23. Ma Y, Zhao M, Zhong J, et al. Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer. J Cell Biochem. 2010;110(6):1512-1519.
24. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology. 2002;40(6):536-546.
25. Chiu C-C, Lin C-Y, Lee L-Y, et al. Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head and neck cancer. Clin Cancer Res. 2011;17(14):4629-4641.
26. Ryu J-S, Shin E-S, Nam H-S, et al. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. J Thorac Oncol. 2011;6(8):1320-1329.
27. Woo HI, Kim K-K, Choi H, et al. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. Pharmacogenomics. 2012;13(9):1023-1035.
28. Babyshkina N, Malinovskaya E, Nazarenko M, et al. The effect of folaterelated SNPs on clinicopathological features, response to neoadjuvant treatment and survival in pre- and postmenopausal breast cancer patients. Gene. 2013;518(2):397-404.
29. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17(3):889-897.
30. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767.
31. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev. 2009;23(3):95-104.
32. Halpern M, Zahalka MA, Traub L, Moroz C. Antibodies to placental immunoregulatory ferritin with transfer of polyclonal lymphocytes arrest MCF-7 human breast cancer growth in a nude mouse model. Neoplasia. 2007;9(6):487-494.
33. Lubecka-Pietruszewska K, Kaufman-Szymczyk A, Stefanska B, Fabianowska-Majewska K. Folic acid enforces DNA methylation-mediated transcriptional silencing of PTEN, APC and RARbeta2 tumour suppressor genes in breast cancer. Biochem Biophys Res Commun. 2013;430(2):623-628.
34. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-410.